On March 30, 2026, Telomir Pharmaceuticals, Inc. announced that it has received a letter from the Nasdaq Capital Markets confirming its compliance with Nasdaq Listing Rule 5620(a). This compliance was achieved following the company's 2025 Annual Meeting of Shareholders. The matter has now been determined as closed by Nasdaq, indicating that the company has met the necessary requirements for maintaining its listing on the exchange. This development is expected to have a small positive effect on the stock price as it reflects the company's adherence to regulatory standards and governance practices. The company continues to operate under the ticker symbol 'TELO' on the Nasdaq Stock Market, and this compliance may enhance investor confidence in its governance and operational execution moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.